Glucos Fresenius Kabi

Glucos Fresenius Kabi is an intravenous solution for injection that contains glucose as the sole active ingredient. The product is supplied in a sterile liquid form, intended for parenteral administration, and is marketed in the European Union for use under prescription. It provides an immediate source of carbohydrate energy and assists in fluid and electrolyte management during clinical care.

Glucos Fresenius Kabi is indicated for several clinical situations where rapid glucose supplementation or fluid replacement is required. It is commonly employed in hospital settings for patients who cannot receive oral nutrition.

- Treatment of hypoglycemia in emergency or perioperative settings - Component of parenteral nutrition regimens for patients requiring intravenous caloric support - Fluid and electrolyte replacement in dehydration or postoperative care - Maintenance of plasma osmolarity during intravenous therapy - Support for patients undergoing dialysis or continuous renal replacement therapy

Glucos Fresenius Kabi is generally well tolerated when administered according to clinical guidelines. Adverse reactions may vary in frequency and severity.

Common: - Local irritation at the infusion site - Mild hyperglycemia - Transient electrolyte imbalance (e.g., sodium, potassium) - Nausea or vomiting - Headache - Flushing or warmth sensation

Serious: - Severe hyperglycemia leading to osmotic diuresis - Allergic reaction such as urticaria or anaphylaxis - Volume overload causing pulmonary edema - Metabolic acidosis in susceptible patients

When using Glucos Fresenius Kabi, clinicians should assess patient-specific factors and monitor relevant parameters to minimize risks.

- Verify blood glucose levels before and during infusion to avoid hyperglycemia - Adjust infusion rate in patients with renal or cardiac insufficiency to prevent fluid overload - Use caution in diabetic patients or those on insulin therapy - Monitor electrolytes, especially sodium and potassium, during prolonged administration - Ensure compatibility with other intravenous solutions to avoid precipitation - Observe for signs of infection at the catheter site

Glucos Fresenius Kabi may interact with other medications or clinical conditions, influencing its safety profile.

Avoid: - Concurrent administration with high‑dose insulin without glucose monitoring - Co‑infusion with calcium-containing solutions that may precipitate - Use in patients with severe hyperglycemia untreated

Use with caution: - Diuretics that affect electrolyte balance - Beta‑blockers that mask hypoglycemia symptoms - Corticosteroids that increase glucose production - Anticoagulants if large fluid volumes are infused rapidly